GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

GSK projects its HIV products will reach £7 billion ($8.5 billion) in sales by 2026, Deborah Waterhouse, CEO of GSK’s specialist HIV company ViiV Healthcare, said Thursday.